254 results about "Microvesicles" patented technology

Contemplated compositions and methods are directed to the use of microvesicles from an optionally recombinant donor cell to impart a desirable effect to a recipient cell. In certain preferred aspects, RNA of the microvesicles is employed to achieve the desirable effect. For example, microvesicles are used in vitro to increase the number of passages of a cell growing in a medium, reduce serum and / or growth factor requirements of a cell growing in a medium, and / or delay differentiation of a cell growing in a medium. Further preferred aspects include use of the microvesicles as therapeutic agents in which RNA, a membrane protein, and / or a cytosolic protein encapsulated in or coupled to the microvesicle provide a therapeutic effect. Additionally, diagnostic methods are contemplated in which RNA of a microvesicle isolated from a mammal is associated with a condition of the mammal.

Disclosed is a method for the treatment and / or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.

Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and / or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

This disclosure provides a method to capture, detect, characterize and quantify human exosomes in small volumes of human body fluids by using a sandwich ELISA test. This method allows a full characterization of an exosome preparation, thus providing a tool to distinguish a disease-related condition from a healthy state, by the use of a non-invasive assay. In fact, this method may be useful in screening, diagnosis and prognosis of tumors, with a simple plasma sample. At the same time measurement of circulating exosomes may provide information on the level of tumor mass present in a patient. The method provided here is suitable to evaluate presence of some infectious and / or transmissible agents, such as viral proteins or prion proteins, within circulating exosomes.

Methods and compositions for diagnosis and / or analysis of a condition in a mammal are disclosed in which RNA from microvesicles is enriched and differentiated to so obtain a result that is indicative of the condition of tissue or organ from which the microvesicle originated. In especially preferred embodiments, the condition is a neoplastic disease of a human and can be identified and staged by differential analysis of one or more distinct RNAs, optionally together with identification and analysis of a non-RNA component of the microvesicle.

The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and / or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

Microvesicles containing interfering RNAs, preparation methods and uses thereof are provided. Pharmaceutical compositions and kits comprising the microvesicles containing interfering RNAs are also provided. Microvesicles containing interfering RNAs, pharmaceutical compositions and kits comprising such microvesicles can be used to study the effects of interfering RNAs on receptor cells. As microvesicles containing interfering RNAs can stably, high efficiently and specifically deliver interfering RNAs, microvesicles containing interfering RNAs can be used to treat related diseases.

Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC may optionally comprise a targeting ligand, a bioactive agent, a diagnostic agent or any combination thereof. The assembly of the invention can be formed from gasfilled microbubbles or microballoons and a MAC having a diameter of less than 100 pm, in particular a micelle and is used as an active component in diagnostically and / or therapeutically active formulations, in particular for enhancing the imaging in the field of ultrasound contrast imaging, including targeted ultrasound imaging, ultrasound-mediated drug delivery and other imaging techniques such as molecular resonance imaging (MRI) or nuclear imaging.

A method of producing a population of differentiated cells comprising: a) inducing differentiation in a first population of cells by applying an inducer to said cells, b) harvesting microvesicles produced from first population of cells, and c) inducing differentiation in a second population of cells by applying said microvesicles or a derivative thereof to said second population of cells wherein, said first population of cells is autologous to said second population of cells and wherein the inducer applied to said first population of cells is not present in said second population of cells or is only present in trace amounts. Also related methods of producing microvesicles, methods of medical and / or cosmetic treatment and related products and uses.

The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of disorders by examining samples containing microvesicles and miRs therein.

The invention discloses an extraction method of a specific mesenchymal stem cell exosome. The method comprises the following steps: collecting supernatant of serum-free mesenchymal stem cells: firstly, culturing mesenchymal stem cells, changing a culture medium for culturing, centrifuging, and removing cell debrises to obtain initial supernatant; taking the initial supernatant for carrying out further gradient centrifugation, transferring the centrifuged supernatant into a sterile centrifugal tube, centrifuging and collecting supernatant containing micro vesicles; centrifuging the supernatantcontaining the micro vesicles to obtain precipitate containing an exosome, washing and then centrifuging to obtain exosome precipitate; adding the obtained exosome precipitate into sterile PBS and filtering to obtain the specific mesenchymal stem cell exosome. The exosome collected in the extraction method disclosed by the invention adopts a filter membrane for filtration, so the extracted exosomeis enabled to be nanoscale; meanwhile, the rotational speed is reduced and optimized, high-speed mechanical damage is reduced, separation efficiency is high and the cost is low.

The present invention provides improved methods and compositions based on microvesicles for the treatment of various diseases, disorders and conditions. In particular, the present invention encompasses the recognition that microvesicles contain specific microRNAs which may function as intercellular regulators involved in cell or tissue regeneration, remodeling, reconstruction, reprogramming or transdifferentiation. Thus, among other things, the present invention provides methods and compositions based on microvesicles and / or associated microRNAs that provide more predictable and effective therapeutic results.

An ultrasonic microvesicle apparatus for directional location and release control of medicine or gene is composed of an ultrasonic triggering-therapeutic unit, a driver unit, an ultrasonic monitor unit, and a computer control unit consisting of host, display, image acquisition card, etc. A method for combining the microvesicle contrast medium with medicine or gene and using ultrasonic wave for target transfer is also disclosed.

The present invention relates to direct protein delivery with engineered micro vesicles.

This document relates to methods and materials involved in identifying calcification (e.g., coronary calcification or soft tissue calcification) in mammals and assessing thrombotic risk in mammals. For example, methods and materials involved in using microvesicles as a marker to determine whether or not a mammal (e.g., a human) has calcification or an elevated risk of thrombosis are provided. In addition, methods and materials for determining the amount and source of microvesicles are provided.

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

A method for the production of stabilized platelets, comprises the steps of: (i) pre-activating platelets, to induce the formation of microvesicles; (ii) contacting the pre-activated platelets with a carbohydrate, whereby the carbohydrate is incorporated into the platelets; and (iii) drying the thus-loaded platelets.

This invention discloses an ultrasonic microbubble contrast agent of carrier gene, it includes microbubble, fluorocarbon gas, gene or medicine. Microbubble wall is made up by lipid bielement, fluorocarbon gas is encapsulated in it, gene or medicine entrapped in microbubble envelope. This invention also discloses its preparation method, two stearyl phosphatidylcholine, two palmitoyl phosphatidyl ethanolamine, sapn-60, glycerol, phosphate buffer solution and gene or medicine is mixed as proper proportion for mechanical oscillations. The property of carry gene or medicine microbubble is stable, particle diameter disperses equally, local tissue medicine concentration can be obviously advanced though effect of transonic breaking microbubble, and curative effect is advanced and side effect can be reduced. Flushing and dilution of blood to gene and medicine can be prevented when used in body, and also prevent gene or medicine from degrading by nuclease in cycle to ensure that lot of gene and medicine can be transported to target tissue. And it is linear increase follow gene or medicine input amount in certain range.

Methods and compositions are provided for oligonucleotides that bind target biomarkers and allow characterization of a phenotype. The target biomarkers may include microvesicle antigens, including microvesicles derived from various diseases. The characterization may comprise detection, diagnosis, prognosis, theranosis or other characterization of a disease or disorder.

A method for using the ultrasonic microvesicle contrast medium as the carrying tool of gene to locate the gene and control to release it to target tissue for transfection. After the contrast medium reaches the target tissue under themonitor of audio-video image, the ultrasonic waves are used to destroy the microvesicle for releasing the gene and performing the gene transfection.

The invention relates to the field of medicines, in particular to a medicine-carrying microvesicle and a preparation method thereof. In the method, medicine-carrying high molecular polymer class nano particles are connected with a lipid microvesicle by an amido bond so as to prepare the medicine-carrying microvesicle. Under an ultrasonic action, the lipid microvesicle of the medicine-carrying microvesicle is broken, and the medicine-carrying high molecular polymer class nano particles which are connected with the lipid microvesicle of the medicine-carrying microvesicle are released and enter the clearances of tissues to exert an action. The method has mild reaction conditions and superior chemical selectivity of the reaction process; and the prepared medicine-carrying microvesicle can be used as an ultrasonic contrast agent, can also be used as a controlled release carrier for various medicines and has extensive application prospect.

Provided herein are stem cell and exosome compositions having therapeutic utility to treat a variety of diseases and disorders, e.g., cardiovascular disease, Duchenne muscular dystrophy, and fibrotic disease.

Assembly comprising a gas-filled microvesicle and a structural entity which is capable to associate through an electrostatic interaction to the outer surface of said microvesicle (microvesicle associated component—MAC), thereby modifying the physico-chemical properties thereof. Said MAC comprises a targeting ligand a diagnostic agent or any combination thereof. Optionally a bioactive agent can further be associated to the MAC. The assembly of the invention can be formed from gas-filled microbubbles or microballoons and a MAC having preferably nanometric dimensions, e.g. a micelle, and is used as an active component in diagnostically and / or therapeutically active formulations, in particular for enhancing the imaging in the field of ultrasound contrast imaging, including targeted ultrasound imaging, ultrasound-mediated drug delivery and and other imaging techniques such as molecular resonance imaging (MRI) or nuclear imaging.

The present invention relates to a therapeutic type ultrasonic microvesicle for tumor ultrasonic therapy, it includes ultrasonic contrast medium microvesicle containing gas endonucleus and blood coagulation factor, the blood coagulation factor is absorbed on the ultrasonic contrast medium microvesicle surface or the blood coagulation factor is adsorbed on the microvesicle surface and covered in its interior so as to form ultrasonic microvesicle in which the blood coagulation factor is combined. Under the proper therapeutic ultrasonic action said therapeutic type ultrasonic microvesicle can promote local tissue microcirculation thrombosis, and can be used for curing the diseases of tumor, etc.

Methods are provided for selecting aptamers that are specific to a target of interest from amongst a library of potential aptamer sequences. Aptamers disclosed can be used to detect and / or characterize biological entities of interest, e.g. microvesicles and / or surface antigens. Further disclosed are biomarkers that can be used for diagnosing different disorders including different types of cancer.

The invention provides compositions of vaporized stem cell derivatives and methods for their use and manufacture in the treatment of skin conditions and other therapeutic applications. Stem cell derivatives comprising vaporized stem cells, stem cell factors and / or stem cell microvesicles are disclosed and contemplated as being within the scope of the invention. The invention finds use in medical, rejuvenative and cosmetic applications.

A method for selectively measuring microvesicles alone in blood by pretreating a sample derived from blood with albumin to selectively eliminate microvesicles alone released from platelets activated by an artificial manipulation.

The invention relates to a method for modifying ligands on the surfaces of cell vesicles. The method comprises the following steps of (a) connecting diphenyl cyclooctyne onto the surfaces of the cell vesicles; (b) removing free diphenyl cyclooctyne; (c) connecting azide-modified ligands onto the diphenyl cyclooctyne on the surfaces of the cell vesicles; (d) performing purification on the modified cell vesicles. Compared with the prior art, the method has the advantages that the time is saved; the process is simple and convenient; the reaction efficiency is high; the ligand types are slightly limited; meanwhile, the physiological activity of the cell vesicles can be maintained to the maximum degree. The treatment effect of the cell vesicles can be favorably enhanced.

Protein enriched micro-vesicles and methods of making and using the same are provided. Aspects of the methods include maintaining a cell having a membrane-associated protein comprising a first dimerization domain and a target protein having a second dimerization domain under conditions sufficient to produce a micro-vesicle from the cell, wherein the micro-vesicle includes the target protein. Also provided are cells, reagents and kits that find use in making the micro-vesicles, as well as methods of using the micro-vesicles, e.g., in research and therapeutic applications.

Microvesicles are small membrane vesicles that either shed or bud off eukarotic cells. Analysis of the nucleic acid content of microvesicles may be useful in detecting the presence or absence of genetic aberrations. This invention discloses novel methods of diagnosing, prognosing, monitoring, or treating a disease, such as cancer, or other medical condition in a subject involving analyzing one or more nucleic acids contained within an isolated microvesicle for the presence or absence of one or more Kras genetic aberrations.